RS54858B1 - Antagonisti trpv4 - Google Patents

Antagonisti trpv4

Info

Publication number
RS54858B1
RS54858B1 RS20160417A RSP20160417A RS54858B1 RS 54858 B1 RS54858 B1 RS 54858B1 RS 20160417 A RS20160417 A RS 20160417A RS P20160417 A RSP20160417 A RS P20160417A RS 54858 B1 RS54858 B1 RS 54858B1
Authority
RS
Serbia
Prior art keywords
3alkyl
het
halo
hydrogen
5alkyl
Prior art date
Application number
RS20160417A
Other languages
English (en)
Inventor
Carl Brooks
Mui Cheung
Hilary Schenck Eidam
Krista B Goodman
Marlys Hammond
Mark A Hilfiker
Tram H Hoang
Jaclyn R Patterson
Patrick Stoy
Guosen Ye
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47558389&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS54858(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of RS54858B1 publication Critical patent/RS54858B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D419/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Jedinjenje Formule (I):naznačeno time, što suR1 je vodonik, C1-3alkil, CH2OH, CH2-O-CH3, CH2OCH2Ph, CH2CN, CN, halo ili C(0)OCH3;R2 je nezavisno vodonik, CN, CF3, halo, SO2C1-3alkil, C1-3alkil ili C=CH;R3 je vodonik, C1-2alkil, CF3 ili OH;R4 je vodonik, halo ili C1-3alkil;X je CR4 ili N;A je (CH2)n-Het; iliA je (CH2)n-(CRaRb)-(CH2)m-Het;Ra je vodonik ili C1-3alkil, pri čemu ovaj C1-3alkil može biti još supstituisan, sa jedan ili više halo;Rb je C1-3alkil;ili, Ra i Rb zajedno sa atomom ugljenika za koji su vezani, formiraju neku C3-6ciklolalkil grupu;ili, jedan ili više atoma ugljenika u ovoj C3-6ciklolalkil grupi, formiranoj sa Ra i Rb, može biti zamenjen sa kiseonikom, formirajući neku oksetan, tetrahidrofuril ili tetrahidropiranil grupu;ili, jedan ili više atoma ugljenika u ovoj C3-6ciklolalkil grupi, formiranoj sa Ra i Rb, može biti zamenjen sa azotom, formirajući neku pirolidinil ili piperidnil grupu;Het je:gde Het može biti supstituisan sa jednim, dva ili tri supstituenta koji se biraju između: halo, C1-5alkil, CN, CH2F, CHF2, CF3, C3-6cikloalkil, (CH2)n-O-C1-3alkil, (CH2)n-fenil, (CH2)n-piridil, pirimidinil, pirazinil, CH(CH3)-O-C1-3alkil, CH(OH)-C1-5alkil, C(CH3)2 - R5, C(O)N(CH3)P, N(C1-3alkil)p, NH2, C(O)NH2, oksetan, oksetan-CH3, tetrahidrofuril, tetrahidropiranil, morfolinil, ili pirazolil; pri čemu ovaj fenil, pirazolil i piridil supstituent na Het može biti još supstituisan sa jednim ili dva supstituenta koji se biraju između: halo, CN, OCH3, C1-3alkil ili CF3;a ovaj C1-5alkil i C3-6cikloalkil supstituent na Het može biti još supstituisan sa CN ili OH;R5 je CN, O-C1-4alkil, (CH2)m-OH, (CH2)p-O-C(O)-O-C1-5alkil, ili O-(CH2)p-O-R6;R6 je C1-4alkil ili P(O)2(CH3)2;n je nezavisno 0, 1 ili 2;m je nezavisno 0, 1 ili 2;p je nezavisno 1 ili 2; iy je1,2 ili 3;ili neka njegova farmaceutski prihvatljiva so.Prijava sadrži još 16 patentnih zahteva.
RS20160417A 2011-06-17 2012-06-15 Antagonisti trpv4 RS54858B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498110P 2011-06-17 2011-06-17
EP12814591.9A EP2721016B1 (en) 2011-06-17 2012-06-15 Trpv4 antagonists
PCT/US2012/042622 WO2013012500A1 (en) 2011-06-17 2012-06-15 Trpv4 antagonists

Publications (1)

Publication Number Publication Date
RS54858B1 true RS54858B1 (sr) 2016-10-31

Family

ID=47558389

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160417A RS54858B1 (sr) 2011-06-17 2012-06-15 Antagonisti trpv4

Country Status (38)

Country Link
US (1) US9187464B2 (sr)
EP (2) EP2721016B1 (sr)
JP (1) JP5969017B2 (sr)
KR (1) KR101870003B1 (sr)
CN (1) CN103732583B (sr)
AR (1) AR086958A1 (sr)
AU (1) AU2012284540B2 (sr)
BR (1) BR112013032391B1 (sr)
CA (1) CA2839743C (sr)
CL (1) CL2013003602A1 (sr)
CO (1) CO6821953A2 (sr)
CR (1) CR20130671A (sr)
CY (1) CY1117792T1 (sr)
DK (1) DK2721016T3 (sr)
DO (1) DOP2013000307A (sr)
EA (1) EA023616B1 (sr)
ES (2) ES2688733T3 (sr)
HK (1) HK1195068A1 (sr)
HR (1) HRP20160539T1 (sr)
HU (1) HUE029594T2 (sr)
IL (1) IL229872A (sr)
JO (1) JO3154B1 (sr)
MA (1) MA35184B1 (sr)
ME (1) ME02416B (sr)
MX (1) MX337440B (sr)
MY (1) MY173521A (sr)
PE (1) PE20141943A1 (sr)
PL (1) PL2721016T3 (sr)
PT (1) PT2721016E (sr)
RS (1) RS54858B1 (sr)
SG (1) SG195106A1 (sr)
SI (1) SI2721016T1 (sr)
SM (1) SMT201600150B (sr)
TW (1) TWI538912B (sr)
UA (1) UA113963C2 (sr)
UY (1) UY34138A (sr)
WO (1) WO2013012500A1 (sr)
ZA (1) ZA201308816B (sr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5969015B2 (ja) 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Trpv4拮抗薬
JP5969016B2 (ja) 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Trpv4拮抗薬
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
JPWO2015046193A1 (ja) 2013-09-25 2017-03-09 塩野義製薬株式会社 Trpv4阻害活性を有する芳香族複素環式アミン誘導体
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
WO2017199199A1 (en) 2016-05-19 2017-11-23 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonist
MA46341A (fr) 2016-10-03 2019-08-07 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
WO2018185701A1 (en) 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists as antitussive agents
CN111278821B (zh) * 2017-11-01 2023-10-03 百时美施贵宝公司 作为法尼醇x受体调节剂的螺环化合物
WO2021170811A1 (en) 2020-02-27 2021-09-02 Glaxosmithkline Intellectual Property (No.2) Limited Method of treating eye disease using trpv4 antagonists
CA3180132A1 (en) 2020-04-30 2021-10-30 Raqualia Pharma Inc. Pyrimidin-4(3h)-one derivatives as trpv4 antagonists
CN111704613B (zh) * 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
CA3189206A1 (en) * 2020-07-16 2022-01-20 Raqualia Pharma Inc. Trpv4 inhibitor as therapeutic agent for ocular disease
TW202409024A (zh) 2022-07-08 2024-03-01 美商愛克堤歐生物科學公司 治療性化合物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1086950B1 (en) * 1998-05-26 2010-09-29 Chugai Seiyaku Kabushiki Kaisha Heterocyclic indole derivatives and mono- or diazaindole derivatives
US7566712B2 (en) * 2003-07-16 2009-07-28 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
CN101346375B (zh) * 2005-11-23 2013-04-10 阿罗斯药物有限责任公司 调节门离子通道用组合物和方法
WO2007067756A2 (en) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CA2634152A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
US20090042897A1 (en) * 2007-02-01 2009-02-12 Glaxo Group Limited Chemical Compounds
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
CN101801953A (zh) * 2007-08-09 2010-08-11 雅培制药有限公司 作为trpv1拮抗剂的四氢吡啶甲酰胺衍生物
TW200944520A (en) 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
JP5607046B2 (ja) * 2008-07-25 2014-10-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Trpv4拮抗薬
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd 2−インドールアクリルアミド類縁体
EP2605658B1 (en) * 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
JP5969016B2 (ja) * 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Trpv4拮抗薬
JP5969015B2 (ja) * 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Trpv4拮抗薬

Also Published As

Publication number Publication date
WO2013012500A1 (en) 2013-01-24
US20140121206A1 (en) 2014-05-01
BR112013032391B1 (pt) 2020-11-24
HK1195068A1 (zh) 2014-10-31
CN103732583B (zh) 2015-12-23
SI2721016T1 (sl) 2016-06-30
IL229872A (en) 2017-03-30
EP3121177B1 (en) 2018-08-01
CL2013003602A1 (es) 2014-07-04
EP2721016A4 (en) 2014-10-08
KR20140041733A (ko) 2014-04-04
EA201490037A1 (ru) 2015-12-30
ME02416B (me) 2016-09-20
DOP2013000307A (es) 2014-06-01
CN103732583A (zh) 2014-04-16
EP2721016B1 (en) 2016-04-06
HUE029594T2 (en) 2017-03-28
TW201313705A (zh) 2013-04-01
JP2014518214A (ja) 2014-07-28
PL2721016T3 (pl) 2017-01-31
AU2012284540A1 (en) 2013-04-04
ES2569193T3 (es) 2016-05-09
EP3121177A1 (en) 2017-01-25
EA023616B1 (ru) 2016-06-30
US9187464B2 (en) 2015-11-17
JO3154B1 (ar) 2017-09-20
PE20141943A1 (es) 2014-12-28
CR20130671A (es) 2014-02-04
SG195106A1 (en) 2013-12-30
KR101870003B1 (ko) 2018-06-22
CA2839743A1 (en) 2013-01-24
BR112013032391A2 (pt) 2016-08-16
ZA201308816B (en) 2015-02-25
SMT201600150B (it) 2016-07-01
CY1117792T1 (el) 2017-05-17
MY173521A (en) 2020-01-30
AR086958A1 (es) 2014-02-05
TWI538912B (zh) 2016-06-21
CA2839743C (en) 2017-03-28
MX2013014898A (es) 2014-03-21
HRP20160539T1 (hr) 2016-06-17
EP2721016A1 (en) 2014-04-23
MA35184B1 (fr) 2014-06-02
DK2721016T3 (en) 2016-06-06
UA113963C2 (xx) 2017-04-10
ES2688733T3 (es) 2018-11-06
NZ618221A (en) 2015-02-27
JP5969017B2 (ja) 2016-08-10
CO6821953A2 (es) 2013-12-31
PT2721016E (pt) 2016-06-06
UY34138A (es) 2013-01-03
MX337440B (es) 2016-03-03
AU2012284540B2 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
RS54858B1 (sr) Antagonisti trpv4
RS54263B1 (sr) Jedinjenja pirolopirimidina kao inhibitori cdk4/6
AR087288A1 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a
EA201591000A1 (ru) Пирролобензодиазепины
RS54175B1 (sr) Inhibitori bromodomena i njihova primena
RS54533B1 (sr) Fenil aminopirimidinska jedinjenja i njihova primena
RS53156B (sr) N1-pirazolospiroketoni kao inhibitori acetil-coa karboksilaze
RS54048B1 (sr) Paraziticidna jedinjenja dihidroizoksazola
MY168201A (en) Agricultural And Horticultural Fungicidal Composition
TW201129558A (en) Piperazine compound having a pgds inhibitory effect
MY177250A (en) Novel nicotinamide derivative or salt thereof
AR085324A1 (es) Composiciones de moleculas pesticidas y proceso de aplicacion de dichas composiciones para controlar acaros, insectos y otras plagas
AR082638A1 (es) Derivados de tetrahidropiran utiles como pesticidas
RS52822B (sr) Uracil spirooksetanski nukleozidi
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
RS54260B1 (sr) Derivati aminodihidrotiazina kao bace inhibitori za tretman alzheimerove bolesti
RS51482B (sr) Derivati 4-(2-amino-1-hidroksietil)fenola kao agonisti 2 adrenergičnih receptora
RS53588B1 (sr) Jedinjenja i kompozicije kao inhibitori protein kinaza
PH12016502037A1 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
AR049291A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
MY152535A (en) Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors
MEP10709A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-alpha]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
MY161094A (en) Anti-tumor effect potentiator
SMT201300085B (it) Composti di pirrolo